Report cover image

Global Gene Modifying Immunotherapy for Blood Cancer Market Growth (Status and Outlook) 2025-2031

Publisher LP Information, Inc.
Published Sep 05, 2025
Length 88 Pages
SKU # LPI20370144

Description

According to this study, the global Gene Modifying Immunotherapy for Blood Cancer market size will reach US$ million by 2031.

Genetic modification immunotherapy for blood cancer is a technique that involves genetic modification of immune system T cells.It allows T cells to recognize weakly expressed antigens in the blood or other organs of the body, such as tumor cells.This form of immunotherapy can be divided into two types: one in which the patient receives genetically modified immune cells from a donor, and the other in which the patient"s own immune cells are removed, genetically modified and then given back to the patient.CAR T cell therapy involves genetically altering immune system T cells to produce a protein called CAR or chimeric antigen receptor protein, which helps T cells attach to specific proteins on the surface of tumor cells, making it easier for them to recognize cancer cells.

United States market for Gene Modifying Immunotherapy for Blood Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Gene Modifying Immunotherapy for Blood Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Gene Modifying Immunotherapy for Blood Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Gene Modifying Immunotherapy for Blood Cancer players cover Novartis, Kite Pharma, Juno Therapeutics, Cellectis, Ziopharm Oncology, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Gene Modifying Immunotherapy for Blood Cancer Industry Forecast” looks at past sales and reviews total world Gene Modifying Immunotherapy for Blood Cancer sales in 2024, providing a comprehensive analysis by region and market sector of projected Gene Modifying Immunotherapy for Blood Cancer sales for 2025 through 2031. With Gene Modifying Immunotherapy for Blood Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Modifying Immunotherapy for Blood Cancer industry.

This Insight Report provides a comprehensive analysis of the global Gene Modifying Immunotherapy for Blood Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Gene Modifying Immunotherapy for Blood Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Modifying Immunotherapy for Blood Cancer market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Modifying Immunotherapy for Blood Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Modifying Immunotherapy for Blood Cancer.

This report presents a comprehensive overview, market shares, and growth opportunities of Gene Modifying Immunotherapy for Blood Cancer market by product type, application, key players and key regions and countries.

Segmentation by Type:
CAR T-cell Therapy
TCR T-cell Therapy

Segmentation by Application:
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
B Cell Lymphoma
Multiple Myeloma
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Kite Pharma
Juno Therapeutics
Cellectis
Ziopharm Oncology
Celyad
Bluebird Bio
Bellicum Pharmaceuticals
Mustang Bio

Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

88 Pages
*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
2 Executive Summary
3 Gene Modifying Immunotherapy for Blood Cancer Market Size by Player
4 Gene Modifying Immunotherapy for Blood Cancer by Region
5 Americas
6 APAC
7 Europe
8 Middle East & Africa
9 Market Drivers, Challenges and Trends
10 Global Gene Modifying Immunotherapy for Blood Cancer Market Forecast
11 Key Players Analysis
12 Research Findings and Conclusion

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us